Daniel Eros, Ph.D.
Affiliations: | 2005 | Semmelweis Egyetem, Hungary |
Area:
Molecular Biology, PharmacyGoogle:
"Daniel Eros"Parents
Sign in to add mentor| Gyorgy Keri | grad student | 2005 | Semmelweis Egyetem | |
| (Structure-activity/property relationships of kinase inhibitors based on calculated and measured parameters, and applications in drug design and development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zsákai L, Sipos A, Dobos J, et al. (2019) Targeted drug combination therapy design based on driver genes. Oncotarget. 10: 5255-5266 |
| Artarini A, Meyer M, Shin YJ, et al. (2019) Regulation of influenza a virus mRNA splicing by CLK1. Antiviral Research |
| Herczenik E, Varga Z, Eros D, et al. (2009) Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. Journal of Receptor and Signal Transduction Research. 29: 75-83 |
| Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, et al. (2009) Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Current Opinion in Molecular Therapeutics. 11: 308-21 |
| Eros D, Orfi L, Csuka I, et al. (2009) Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Amino Acids. 36: 483-92 |
| Eros D, Szántai-Kis C, Kiss R, et al. (2008) Structure -activity relationships of PDE5 inhibitors. Current Medicinal Chemistry. 15: 1570-85 |
| Székely R, Wáczek F, Szabadkai I, et al. (2008) A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunology Letters. 116: 225-31 |
| Szántai-Kis C, Kövesdi I, Eros D, et al. (2006) Prediction oriented QSAR modelling of EGFR inhibition. Current Medicinal Chemistry. 13: 277-87 |
| Keri G, Orfi L, Eros D, et al. (2006) Signal transduction therapy with rationally designed kinase inhibitors Current Signal Transduction Therapy. 1: 67-95 |
| Székelyhidi Z, Pató J, Wáczek F, et al. (2005) Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorganic & Medicinal Chemistry Letters. 15: 3241-6 |